Pharmacotherapy for the management of cancer regimen-related oral mucositis

References

• Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book. 2013;33.e236.
   PubMedGoogle Scholar
• Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–1461.
   PubMed Web of Science ®Google Scholar
• Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704–2713.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19(8):2201–2205.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Eilers JP, Epstein JB, et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer. 1999;85(10):2103–2113.
   PubMed Web of Science ®Google Scholar
• Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52(1):61–77, viii.
   PubMedGoogle Scholar
• Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5(9 Suppl 4):3–11. .
   PubMedGoogle Scholar
• Murphy BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol. 2007;5(9Suppl 4):13–21.
   PubMedGoogle Scholar
• Mortensen HR, Overgaard J, Specht L, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012;103(1):69–75.
   PubMed Web of Science ®Google Scholar
• Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–831.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995–2025.
   PubMed Web of Science ®Google Scholar
• Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy–European blood and marrow transplantation mucositis advisory group. J Clinical Oncology. 2008;26(9):1519–1525.
   PubMed Web of Science ®Google Scholar
• Sonis ST. Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol. 2009;45(12):1015–1020.
   PubMed Web of Science ®Google Scholar
• Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103(6):1165–1171.
   PubMed Web of Science ®Google Scholar
• Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20(6):1491–1498.
   PubMed Web of Science ®Google Scholar
• Chen E Impact of Addison’s Disease and Psoriasis on the Frequency of Oral Mucositis [ Thesis Harvard School of Dental Medicine]. 2003.
   Google Scholar
• Bensinger W, Schubert M, Ang KK, et al. NCCN task force report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008;6(Suppl 1):S1–S21;quiz S2–4.
   PubMedGoogle Scholar
• Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori. 2006;92(2):87–91.
   PubMed Web of Science ®Google Scholar
• Peterson DE, Keefe DM, Sonis ST. New frontiers in mucositis. Am Soc Clin Oncol Educ Book. 2012;32:545–551.
   PubMedGoogle Scholar
• Sonis ST, Scherer J, Phelan S, et al. The gene expression sequence of radiated mucosa in an animal mucositis model. Cell Prolif. 2002;35(Suppl 1):93–102.
   PubMed Web of Science ®Google Scholar
• Sonis S, Haddad R, Posner M, et al. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Oral Oncol. 2007;43(3):289–300.
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, et al. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther. 2008;7(7):1139–1145.
   PubMed Web of Science ®Google Scholar
• Ong ZY, Gibson RJ, Bowen JM, et al. Pro-inflammatory cytokines play a key role in the development of radiotherapy-induced gastrointestinal mucositis. Radiat Oncol. 2010;5:22.
   PubMed Web of Science ®Google Scholar
• Murphy CK, Fey EG, Watkins BA, et al. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2008;14(13):4292–4297.
   PubMed Web of Science ®Google Scholar
• Pratesi N, Mangoni M, Mancini I, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol. 2011;99(3):356–361.
   PubMed Web of Science ®Google Scholar
• Sonis S, Antin J, Tedaldi M, et al. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Diseases. 2013;19(7):721–727.
   PubMed Web of Science ®Google Scholar
• Coleman EA, Lee JY, Erickson SW, et al. GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis. Support Care Cancer. 2015;23(3):841–849.
   PubMed Web of Science ®Google Scholar
• Bogunia-Kubik K, Mazur G, Urbanowicz I, et al. Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. Int J Immunogenet. 2006;33(1):21–24.
   PubMed Web of Science ®Google Scholar
• Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13(5):380–389.
   PubMedGoogle Scholar
• Logan RM, Gibson RJ, Sonis ST, et al. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43(4):395–401.
   PubMed Web of Science ®Google Scholar
• Logan RM, Gibson RJ, Bowen JM, et al. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62(1):33–41.
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, et al. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007;33(5):448–460.
   PubMed Web of Science ®Google Scholar
• Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277–284.
   PubMed Web of Science ®Google Scholar
• Vasconcelos RM, Sanfilippo N, Paster BJ, et al. Host-microbiome cross-talk in oral mucositis. J Dent Res. 2016;95(7):725–733.
   PubMed Web of Science ®Google Scholar
• Djuric M, Hillier-Kolarov V, Belic A, et al. Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer. 2006;14(2):137–146.
   PubMed Web of Science ®Google Scholar
• Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351(25):2590–2598.
   PubMed Web of Science ®Google Scholar
• Yuan A, Sonis S. Emerging therapies for the prevention and treatment of oral mucositis. Expert Opin Emerg Drugs. 2014;19(3):343–351.
   PubMed Web of Science ®Google Scholar
• Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3179–3189.
   PubMed Web of Science ®Google Scholar
• Sonis S, Watkins E, Yuschak M, et al. Mechanism of action of benzydamine in the treatment of oral mucositis. J Clin Oncol. 2005;23(16S): 8040.
   Google Scholar
• Melo ML, Brito GA, Soares RC, et al. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol. 2008;61(5):775–784.
   PubMed Web of Science ®Google Scholar
• Ferra C, de Sanjose S, Lastra CF, et al. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications. Bone Marrow Transplant. 1997;20(12):1075–1080.
   PubMed Web of Science ®Google Scholar
• Sonis ST, Peterson RL, Edwards LJ, et al. Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. 2000;36(4):373–381.
   PubMed Web of Science ®Google Scholar
• Moslehi A, Taghizadeh-Ghehi M, Gholami K, et al. N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Bone Marrow Transplant. 2014;49(6):818–823. .
   PubMed Web of Science ®Google Scholar
• Keefe DM, Sonis ST, Bowen JM. Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008;13(3):511–522.
   PubMed Web of Science ®Google Scholar
• Oberoi S, Zamperlini-Netto G, Beyene J, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Plos One. 2014;9(9):e107418.
   PubMed Web of Science ®Google Scholar
• Lopes NN, Plapler H, Chavantes MC, et al. Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer. 2009;17(11):1409–1415.
   PubMed Web of Science ®Google Scholar
• Basso FG, Oliveira CF, Kurachi C, et al. Biostimulatory effect of low-level laser therapy on keratinocytes in vitro. Lasers Med Sci. 2013;28(2):367–374.
   PubMed Web of Science ®Google Scholar
• Kujawa J, Zavodnik L, Zavodnik I, et al. Effect of low-intensity (3.75-25 J/cm2) near-infrared (810 nm) laser radiation on red blood cell ATPase activities and membrane structure. J Clin Laser Med Surg. 2004;22(2):111–117.
   PubMedGoogle Scholar
• Sonis ST, Hashemi S, Epstein JB, et al. Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol. 2016;54:7–14.
   PubMed Web of Science ®Google Scholar
• Allison RR, Ambrad AA, Arshoun Y, et al. Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer. 2014;120(9):1433–1440.
   PubMed Web of Science ®Google Scholar
• Buchsel PC. Polyvinylpyrrolidone-sodium hyaluronate gel (Gelclair): a bioadherent oral gel for the treatment of oral mucositis and other painful oral lesions. Expert Opin Drug Metab Toxicol. 2008;4(11):1449–1454.
   PubMed Web of Science ®Google Scholar
• Quinn B. Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy: a review of current data. Eur J Cancer Care. 2013;22(5):564–579.
   PubMed Web of Science ®Google Scholar
• Raphael MF, den Boer AM, Kollen WJ, et al. Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children? Results from a prospective multicenter double blind randomized controlled trial. Support Care Cancer. 2014;22(1):3–6.
   PubMed Web of Science ®Google Scholar
• Dodd MJ, Dibble SL, Miaskowski C, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(1):39–47.
   PubMed Web of Science ®Google Scholar
• Nomura M, Kamata M, Kojima H, et al. Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis. Ann Oncology. 2013;24(4):1062–1066.
   PubMed Web of Science ®Google Scholar
• Limaye SA, Haddad RI, Cilli F, et al. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer. 2013;119(24):4268–4276.
   PubMed Web of Science ®Google Scholar